Basecamp Research has raised $140 million in an oversubscribed Series C that values the London company at $800 million, more than triple its last known valuation.
S32, a fund tied to Google co-founder Bill Maris, led the round. Nvidia, Anthropic’s Anthology Fund, the NATO Innovation Fund, the Rockefeller Foundation, Catalio Capital Management, True Ventures and Redalpine joined. Andre Hoffmann, vice-chairman of Roche, invested as an individual.
EDEN is the company’s biological foundation model, and it carries 28 billion parameters. Training data comes from the Trillion Gene Atlas, assembled under access and benefit-sharing deals struck in more than 30 countries. Basecamp puts the atlas at over 100 billion genes.
Its first target is in vivo cell therapy: designing long DNA sequences and delivering them so a patient’s own cells are reprogrammed inside the body, rather than extracting cells, engineering them at a plant and reinfusing them. The external route carries manufacturing costs that can run into the hundreds of thousands of dollars per patient, which is where Basecamp sees room for a cheaper design.
Founders Glen Gowers and Oliver Vince met at Oxford and later ran off-grid DNA sequencing on an Icelandic ice cap. The company keeps sites in Clerkenwell and Cambridge, Massachusetts.
Having Anthropic’s fund and Nvidia on the cap table matters beyond the cash. Both supply models or compute, and both now hold a stake in biological data moving from public repositories toward curated, commercially licensed collections.
